Peer Review reports
From: Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
| Original Submission | ||
|---|---|---|
| 13 May 2019 | Submitted | Original manuscript |
| 30 Oct 2019 | Reviewed | Reviewer Report - Joseph C. del Paggio |
| 23 Mar 2020 | Reviewed | Reviewer Report |
| 4 May 2020 | Author responded | Author comments - Fei Liang |
| Resubmission - Version 2 | ||
| 4 May 2020 | Submitted | Manuscript version 2 |
| 12 May 2020 | Reviewed | Reviewer Report |
| 12 Jul 2020 | Reviewed | Reviewer Report |
| 7 Aug 2020 | Author responded | Author comments - Fei Liang |
| Resubmission - Version 3 | ||
| 7 Aug 2020 | Submitted | Manuscript version 3 |
| 14 Aug 2020 | Author responded | Author comments - Fei Liang |
| Resubmission - Version 4 | ||
| 14 Aug 2020 | Submitted | Manuscript version 4 |
| Publishing | ||
| 18 Aug 2020 | Editorially accepted | |
| 31 Aug 2020 | Article published | 10.1186/s12885-020-07313-2 |
You can find further information about peer review here.